title: Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
abstract: Chronic myeloid leukemia (CML) depends on the kinase activity of the BCR-ABL1 fusion protein. This dependency has led to the development of BCR-ABL1 inhibitors, such as imatinib, dasatinib, and nilotinib, which have proved to be highly efficacious treatments for CML. The European LeukemiaNet guidelines have established the importance of achieving a certain depth of response at different time points during imatinib therapy for patients with newly diagnosed CML in chronic phase. Patients who achieve a complete cytogenetic response by 12 months or a major molecular response by 18 months are classified as optimal responders and deemed to have excellent long-term outcomes. Conversely, failing to achieve such milestones is associated with an increased risk of worse long-term outcomes, such as loss of response, disease progression, or death. With ongoing treatment, patients not in complete cytogenetic response face a decreasing probability of ever achieving a complete cytogenetic response or major molecular response and increasing risk of disease progression. Available data therefore support treatment recommendations based on achieving defined levels of response within a specified duration of treatment. Recent data have shown that dasatinib and nilotinib used as frontline CML therapy result in higher response rates that are achieved at earlier time points compared with standard-dose imatinib therapy. Future analyses will need to determine whether these higher rates of deep and fast responses translate into improved long-term survival.
authors: Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. aquintas@mdanderson.org
authors: Alfonso
authors: A
authors: Quintás-Cardama
authors: Jorgé E
authors: JE
authors: Cortes
authors: Hagop M
authors: HM
authors: Kantarjian
references: Blood. 2008 Oct 15;112(8):3330-8
references: 18684859
references: Haematologica. 2008 Dec;93(12):1765-9
references: 19050065
references: Leukemia. 2002 Jan;16(1):53-9
references: 11840263
references: Cancer Cell. 2005 Feb;7(2):129-41
references: 15710326
references: Cancer Res. 2006 Jun 1;66(11):5790-7
references: 16740718
references: Blood. 2009 Feb 19;113(8):1619-30
references: 18827185
references: Blood. 2008 Dec 1;112(12):4437-44
references: 18716134
references: Curr Oncol Rep. 2009 Sep;11(5):337-45
references: 19679008
references: J Clin Oncol. 2010 Jan 20;28(3):398-404
references: 20008620
references: N Engl J Med. 2010 Jun 17;362(24):2251-9
references: 20525993
references: Cancer Res. 2005 Jun 1;65(11):4500-5
references: 15930265
references: N Engl J Med. 2003 Oct 9;349(15):1423-32
references: 14534335
references: N Engl J Med. 2001 Apr 5;344(14):1031-7
references: 11287972
references: Blood. 2006 Sep 15;108(6):1809-20
references: 16709930
references: Leukemia. 2009 Jun;23(6):1054-61
references: 19282833
references: Cancer. 2008 Feb 15;112(4):837-45
references: 18085610
references: N Engl J Med. 2006 Dec 7;355(23):2408-17
references: 17151364
references: Blood. 2009 Jun 18;113(25):6315-21
references: 19369233
references: J Clin Oncol. 2008 Aug 20;26(24):3913-5
references: 18711176
references: J Clin Oncol. 1983 Nov;1(11):710-9
references: 6668489
references: J Natl Cancer Inst. 1998 Jun 3;90(11):850-8
references: 9625174
references: J Clin Oncol. 2009 Dec 10;27(35):6041-51
references: 19884523
references: Cancer. 2006 Mar 15;106(6):1306-15
references: 16463391
references: J Clin Oncol. 2008 Jul 10;26(20):3358-63
references: 18519952
references: Cancer. 2007 Apr 15;109(8):1556-60
references: 17342766
references: Cancer. 2009 Aug 15;115(16):3709-18
references: 19517462
references: Leukemia. 2003 Dec;17(12):2401-9
references: 14523461
references: J Clin Oncol. 2010 Jan 20;28(3):424-30
references: 20008622
references: Genes Chromosomes Cancer. 1993 Dec;8(4):237-45
references: 7512367
references: Blood. 2009 Dec 3;114(24):4939-43
references: 19797518
references: N Engl J Med. 2003 Mar 13;348(11):994-1004
references: 12637609
references: Blood. 2003 Jan 1;101(1):97-100
references: 12393600
references: Blood. 1984 Apr;63(4):789-99
references: 6584184
references: Blood. 2010 Nov 11;116(19):3758-65
references: 20679528
references: N Engl J Med. 2010 Jun 17;362(24):2260-70
references: 20525995
references: Blood. 2006 Jul 1;108(1):28-37
references: 16522812
references: Blood. 2009 Dec 3;114(24):4933-8
references: 19822896
references: Cancer. 2009 Jul 1;115(13):2912-21
references: 19402171
references: J Clin Oncol. 2010 Jan 20;28(3):392-7
references: 20008621